Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
30 Novembro 2022 - 2:30PM
Business Wire
MedinCell (Paris:MEDCL) has received an
additional US$ 4 million payment from the Bill & Melinda Gates
Foundation
This amount is intended to finance the next steps of
MedinCell’s program mdc-WWM in readiness to initiate the first
clinical trial end of 2023
It follows US$ 11,8 million already received as part of the
two successive grants for a total of up to US$ 22,5 million from
the Bill & Melinda Gates Foundation to finance the development
of the program up to phase 1 completion
The Gates Foundation has a non-exclusive license on the
product for the purposes of achieving Global Access in the target
low-and middle-income countries, whilst MedinCell owns all
marketing rights worldwide
Access here the complete press release
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. MedinCell collaborate with tier
one pharmaceuticals companies and foundations to improve Global
Health through new therapeutic options. Based in Montpellier,
MedinCell currently employs more than 150 people representing over
30 different nationalities. www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221130005950/en/
MedinCell David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Olivier Bricaud Investor
Relations medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
